Featured News

Does living with celiac disease impact your daily life? We need your help to advance celiac disease research and test an investigational medication.  

Have you ever been asked to join a clinical trial for celiac disease? If you have considered participating, what would make you feel safe, informed, and motivated to participate? These…

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

People with celiac disease have a small but significantly increased mortality rate. The finding comes from the largest study of its kind, which used long-term health records of celiac patients in Sweden between 1969 and 2017.

Data from the Nexvax2 study shows celiac patients exposed to gluten react within two hours and experience nausea and vomiting, not the classic lower digestive symptoms commonly associated with celiac disease.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

The Center for Celiac Research at Massachusetts General Hospital, MassGeneral Hospital for Children, and the Celiac Research Program at Harvard Medical School, recently launched the Celiac Disease Genomic Environmental Microbiome and…